The use of medicinal cannabis, also known as medical marijuana, entails the use of Cannabis sativa and Cannabis indica or their extracts to treat disease symptoms or health conditions. Proponents in modern medicine have strongly vouched for the therapeutic potential of this plant, leading to its legalization for medicinal use in many jurisdictions worldwide. This article will explore the myriad of health benefits attributed to medicinal cannabis.

1. Pain Relief

Chronic pain, a condition affecting a staggering more than 25% of the global population, is a significant global health concern, as reported by the World Health Organization (WHO). It is a relentless and often debilitating health issue that seriously impairs an individual’s quality of life, leading to decreased productivity, poor mental health, and overall reduced life satisfaction. To manage this persistent pain, an increasingly large number of people are turning towards an alternative, yet potent, pain management option – medicinal cannabis. Cannabis, a plant with a rich history of medicinal use dating back thousands of years, contains active compounds known as cannabinoids. These cannabinoids are often reported to possess potent analgesic or pain-relieving properties. They work by interacting with the body’s endocannabinoid system, a complex cell-signaling system responsible for maintaining bodily homeostasis. This interaction results in a variety of physiological effects, one of which is the reduction of pain perception, offering significant relief to those impacted by chronic pain conditions. There are over a hundred different cannabinoids found in cannabis, but the two primary and most researched are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the psychoactive compound responsible for the ‘high’ associated with recreational cannabis use. However, in the context of pain management, it has been acknowledged for its analgesic effects and its ability to reduce nausea and increase appetite, making it especially useful for patients undergoing chemotherapy. On the other hand, CBD is non-psychoactive and has gained acclaim for its wide range of therapeutic benefits without the intoxicating effects. It has been recognized for its potential in reducing inflammation and pain, along with its neuroprotective properties. Many studies suggest that CBD could potentially be beneficial for a plethora of health conditions, further increasing its appeal as a medicinal aid. Operating in tandem, THC and CBD interact with the body’s endocannabinoid system, leading to effective pain reduction and relief from other symptoms. This interaction is what makes medicinal cannabis a potent alternative in managing conditions associated with chronic pain. These conditions span a wide array of health issues, including but not limited to multiple sclerosis, arthritis, fibromyalgia, endometriosis, and migraines. Multiple sclerosis, for example, is a debilitating neurological condition wherein the immune system erroneously attacks the protective cover of nerve fibers. This results in communication problems between the brain and the rest of the body, leading to persistent pain among other symptoms. Arthritis, which is characterized by inflammation and pain in the joints, and fibromyalgia, a condition that causes muscle pain and fatigue, also significantly benefit from the pain-relieving properties of cannabinoids. In conclusion, the advent of medicinal cannabis as a potential management tool for chronic pain demonstrates a promising shift in the world of medicine. Its use signals a move towards more personalized, patient-centered care that is both respectful of patient choice and cognizant of the need for effective pain management strategies. As research into the therapeutic benefits of cannabis and its cannabinoids continues to evolve, it offers hope for the millions of people worldwide living with chronic pain.

2. Cancer Treatment Support

Numerous studies conducted across the globe have started to suggest that medicinal cannabis can be a potentially effective tool in managing the often debilitating side effects that are associated with cancer treatment. Specifically, the side effects caused by chemotherapy, which is a common treatment method for cancer, can often result in patients suffering from severe bouts of nausea and vomiting. These symptoms significantly hamper the quality of life for these patients, and can often be as distressing as the disease itself. However, evidence is mounting that the use of medicinal cannabis can help alleviate these symptoms and provide a much-needed respite for patients undergoing such treatments. The active ingredients in cannabis, commonly referred to as cannabinoids, are thought to be responsible for this beneficial effect. Cannabinoids interact with the endocannabinoid system in our body, a complex cell-signaling system, and may help in reducing nausea and vomiting. Some studies have shown that medicinal cannabis can be more effective than conventional anti-nausea medications, opening up a new avenue of treatment for cancer patients. Moreover, ongoing research into the potential benefits of medicinal cannabis has also begun to suggest that cannabinoids may have a more direct role in the battle against cancer. Some studies have indicated that these compounds may slow the growth of certain types of cancer. This is a promising avenue of research, as limiting the growth of cancer cells can increase the chances of successful treatment and survival. The exact mechanism of how cannabinoids inhibit cancer growth is not fully understood yet. There’s some evidence to suggest that they may interfere with the division of cancer cells, preventing them from multiplying and spreading. They might also block the development of blood vessels required by the tumors to grow, thereby effectively starving the cancerous cells. Despite these promising signs, it’s important to note that much more rigorous and comprehensive research is required to conclusively substantiate these claims. While the existing body of research is encouraging, it’s still relatively small compared to the breadth of knowledge available for more traditional cancer treatments. Additionally, the complexity and variability of cancer indicate that even if cannabinoids are effective against certain types of the disease, they may not work for all types. It’s also crucial to consider the potential side effects and risks associated with medicinal cannabis. Just like any other drug, cannabinoids may have their own set of side effects which need to be studied in-depth. In conclusion, while the potential of medicinal cannabis in managing the side effects of chemotherapy and possibly slowing the growth of certain types of cancer is indeed intriguing, the call for more rigorous research, comprehensive studies, and clinical trials is warranted. Only with a more robust understanding of the benefits and risks can we truly harness the potential of this promising treatment approach.

3. Neurological and Mental Disorders

Therapeutic potential for medicinal cannabis, colloquially termed medical marijuana, is being increasingly acknowledged in managing a variety of neurological disorders. These disorders, including epilepsy, Parkinson’s disease, and multiple sclerosis, present unique management challenges. A more in-depth comprehension of cannabis’s role could catalyze a comprehensive approach to neurological care. Epilepsy, defined by recurrent seizures, has shown encouraging improvement with medicinal cannabis. These seizures severely diminish quality of life and often resist control by conventional antiepileptic drugs. Epidiolex, a purified cannabidiol (CBD) extract and FDA-approved drug, exemplifies the potential of cannabis. Unlike tetrahydrocannabinol (THC), another principal compound in cannabis, CBD is devoid of intoxicating effects. Instead, it has proven medical benefits, including anti-inflammatory and neuroprotective properties. Used in treating severe epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome in patients aged two and above, Epidiolex has demonstrated marked reductions in seizure frequency. These results highlight the potential of purified CBD extracts as an efficacious alternative for patients resistant to conventional treatments. Parkinson’s disease, a degenerative nervous system disorder, has also shown improvement with medicinal cannabis use. Characterized by tremors, stiffness, and balance and coordination issues, the symptoms are caused by the gradual loss of dopamine-producing nerve cells in the brain. Medical marijuana can potentially alleviate these symptoms, attributing to its anti-inflammatory and antioxidant properties. Cannabinoids in cannabis might interact with the brain’s endocannabinoid system, thereby possibly reducing motor symptom severity. Multiple sclerosis, an autoimmune disorder damaging nerve cell covering in the brain and spinal cord, may also benefit from medicinal cannabis. Research suggests that cannabis can aid in muscle spasticity, a prevalent symptom in MS patients, by potentially mitigating the immune response and inflammation. Medicinal cannabis exhibits significant potential in managing various neurological conditions. The journey from standard antiepileptic drugs to Epidiolex, a purified CBD extract, represents a significant milestone. Nevertheless, ongoing research is imperative to fully comprehend the potential benefits and risks of cannabis in neurological disorders. It offers hope for improved patient quality of life, necessitating careful regulation and monitoring to prevent dependency or other harmful effects. Furthermore, medicinal cannabis has been utilized in mental health therapy, potentially alleviating post-traumatic stress disorder (PTSD), depression, and anxiety symptoms. It’s vital, however, to recognize the complex relationship between cannabis and mental health, as indiscriminate use could exacerbate symptoms.

4. Sleep Management

The therapeutic, sedative effects of specific strains of cannabis have been widely renowned for the potential relief they can provide to those individuals who grapple with insomnia or various other disruptive sleep disorders. These strains are specifically cultivated and harvested to harness their calming qualities, promoting relaxation and an overall feeling of tranquility. Insomnia, as a condition, can be extremely debilitating for individuals, affecting productivity and overall health. The constant struggle of falling asleep and staying asleep throughout the night can be exhausting and can significantly affect quality of life. The same can be said for other sleep disorders such as sleep apnea, restless leg syndrome, and narcolepsy. So, the fact that certain strains of cannabis can potentially alleviate such conditions is a significant development in the world of alternative medicine and sleep therapy. The impact of these specific cannabis strains is not only direct – in helping individuals achieve a peaceful night’s sleep, but also indirect – by targeting and mitigating the conditions known to cause sleep disturbances. These conditions could span from physical discomfort and chronic pain to mental health conditions like anxiety and Post-Traumatic Stress Disorder (PTSD). Chronic pain is known to be a leading cause of sleep disturbances, with patients finding it difficult to find a comfortable position for uninterrupted sleep. Moreover, the constant discomfort can lead to increased stress levels, further exacerbating the sleep problem. The use of medicinal cannabis can actively reduce this pain, thereby indirectly promoting better sleep patterns. Likewise, mental health conditions such as anxiety and PTSD can significantly disrupt sleep. The heightened sense of fear and stress that individuals with anxiety and PTSD experience can lead to nightmares and interrupted sleep patterns, consequently leading to chronic fatigue and other health issues. The calming effects of medicinal cannabis can help to reduce this fear and stress, allowing for a more peaceful and restful sleep. Therefore, the utilization of medicinal cannabis is not merely about promoting sleep, but more about targeting the root causes of sleep disturbances and effectively managing them. By providing relief from conditions such as chronic pain, anxiety, and PTSD, medicinal cannabis paves the way for improved sleep quality and, ultimately, improved overall wellbeing. It’s important to note, however, that while the potential benefits of medicinal cannabis are promising, it should always be used under the guidance and supervision of a healthcare professional.

5. Appetite Stimulation

Cannabis, also commonly referred to as marijuana, is a plant that has been consistently linked to hunger stimulation, a characteristic that has brought it into the spotlight in medical and scientific circles. The appetite-inducing properties of cannabis are not just a matter of popular discourse, but have been thoroughly researched and documented in numerous medical studies. This attribute of cannabis has shown significant potential in the field of medical treatment, particularly for conditions where loss of appetite is a major concern. One such instance where cannabis is an important consideration is in the management of HIV/AIDS. Individuals suffering from HIV/AIDS often experience a debilitating loss of appetite, leading to acute weight loss and malnutrition, which severely affects their overall health status. This is not just a side effect of the disease itself, but can also be triggered by the potent antiretroviral drugs used in the treatment of HIV/AIDS. The hunger-stimulating properties of cannabis can be harnessed to counter this effect, helping to increase food intake, improve nutritional status, and enhance the quality of life in these patients. Similarly, certain types of cancers are known to cause significant loss of appetite and drastic weight loss. This phenomenon, often referred to as ‘cachexia’, is a complex metabolic syndrome associated with underlying illness and characterized by muscle mass loss with or without fat mass loss. It can lead to severe physical impairment and can drastically reduce the patient’s chances of survival. In such scenarios, cannabis can serve as an effective therapeutic intervention. Its appetite-stimulating properties can help cancer patients maintain their body weight and potentially offset the muscle wasting associated with cachexia. However, it’s important to note that the use of cannabis in medical treatment should not be self-administered or improvised. It requires meticulous monitoring by healthcare professionals to ensure appropriate dosage and to manage any potential side effects. The use of cannabis for appetite stimulation is typically via medical marijuana, which is prescribed and monitored by a qualified physician. The potential of cannabis in the treatment of conditions causing significant loss of appetite and severe weight loss is something that warrants further research and investigation. It’s a remarkable testament to the diverse applications of this plant in medicine. However, its use should always be under the guidance of a healthcare professional to ensure patient safety and efficacy.

6. Glaucoma Treatment

Glaucoma is a serious eye condition that can cause gradual sight deterioration and eventually lead to complete blindness. This disease primarily affects the optic nerve, which serves as a crucial link between the eye and the brain, transmitting visual information in the form of nerve impulses. The primary cause of optic nerve damage in glaucoma patients is an increase in pressure within the eyeball, also known as intraocular pressure. This heightened pressure can gradually wear down the optic nerve over time, which can lead to vision loss. The disease typically begins with minor vision changes and slowly escalates into significant vision loss, making it all the more dangerous as it often goes undetected until the later, more devastating stages. The vision loss caused by glaucoma is typically irreversible and as such, it’s crucial to slow the progression of the disease as soon as possible, preserving whatever vision remains. Interestingly, research in recent years has shown that cannabis, a plant often associated with recreational use, might hold potential benefits for those suffering from glaucoma. The active components of cannabis, particularly tetrahydrocannabinol (THC), have been demonstrated to significantly lower intraocular pressure in both normal individuals and those with glaucoma. This reduction in eye pressure can help slow the disease’s progression, potentially saving individuals from severe vision loss or even total blindness. When consumed, these active cannabinoids interact with cannabinoid receptors in the eye to decrease the production of aqueous humor – the fluid that maintains eye pressure – and increase its outflow. This dual-action effect can significantly reduce intraocular pressure, thus alleviating one of the primary risk factors associated with glaucoma. It is essential to note, however, that while cannabis has shown potential in managing glaucoma, it is not yet a universally accepted method of treatment. Moreover, like all medications, cannabis use comes with its side effects. Some common ones include dizziness, anxiety, and changes in heart rate and blood pressure. Therefore, it’s crucial for individuals to consult with their healthcare provider before considering cannabis as a treatment option for glaucoma. In conclusion, while glaucoma remains a significant threat to vision health, innovative research into alternative treatments like cannabis provides a glimmer of hope. Further research and clinical trials are needed to fully understand the potential benefits and drawbacks of cannabis as a treatment option for glaucoma. Nevertheless, its ability to lower intraocular pressure and slow the progression of the disease signals a promising way forward in the ongoing battle against this debilitating eye condition.

7. Alcoholism and Drug Addiction Treatment

In the realm of contemporary scientific and medical research, a multitude of studies have raised the potential of medicinal cannabis as a viable alternative to opioids for the management of chronic pain. This emerging research posits that the use of medicinal cannabis might not only prove to be a safer alternative, but it also bears the potential to significantly reduce opioid dependence, which has become a major public health concern. The main advantage of medicinal cannabis over opioids, according to these studies, is its remarkable safety profile. Unlike opioids, which can lead to fatal overdose, cannabis is virtually impossible to fatally overdose on. This is due to the fact that cannabinoid receptors, unlike opioid ones, are not located in the parts of the brain that control vital functions like respiration. Therefore, assuming one uses it responsibly and under the guidance of a healthcare provider, cannabis presents a much lower risk of fatal overdose. Furthermore, it’s also been noted that the side effects of cannabis, including dry mouth and feeling high, are generally less severe than the side effects associated with opioid use, such as the risk of addiction, respiratory depression, and death. Moreover, several studies have demonstrated that states with legalized medicinal cannabis have reported substantial decreases in opioid-related deaths and hospitalisations. This statistic is a clear indication of the potential that medicinal cannabis holds in the battle against opioid dependency, and it underscores the necessity for further research and policy changes to facilitate its use. In addition to its potential role in managing chronic pain and reducing opioid dependence, medicinal cannabis is also under scientific investigation for its prospective role in treating other substance use disorders. One area of specific interest is alcoholism. Research suggests that cannabinoids might help reduce the physical and psychological symptoms of alcohol withdrawal. Furthermore, studies have shown that certain cannabis compounds might help reduce alcohol consumption by influencing the reward system in the brain, which could potentially help individuals with alcoholism in their recovery process. Preliminary evidence also suggests that cannabis could play a role in treating other substance use disorders, including stimulant and benzodiazepine dependence. The benefits of cannabis in such scenarios could be attributed to its ability to alleviate withdrawal symptoms, reduce cravings, and in some cases, substitute the effects of more harmful substances. While these findings are encouraging, it’s important to remember that this field of research is still in its infancy. Further comprehensive studies are needed to fully understand the potential benefits and drawbacks of medicinal cannabis for the treatment of chronic pain and substance use disorders. Furthermore, it’s crucial that medicinal cannabis is used responsibly and under the guidance of healthcare providers to ensure its potential benefits are fully realized while minimizing any associated risks. In conclusion, the use of medicinal cannabis is showing promising potential as a safer alternative to opioids for chronic pain management and it’s also being studied for its potential role in treating other substance use disorders, including alcoholism. However, more research is crucial to substantiate these promising early findings and to develop sound cannabis-based therapies that can be integrated into mainstream medical practices.

8. Multiple Sclerosis

The potential therapeutic benefits of medicinal cannabis, particularly in the field of neurology, have been the subject of numerous scientific studies in recent years. One area of study that has garnered considerable attention is the potential for medicinal cannabis to provide relief for the painful symptoms associated with multiple sclerosis, a debilitating neurological disease that affects millions of individuals worldwide. Multiple sclerosis is characterized by a range of uncomfortable and progressive symptoms, such as spasms, numbness, problems with balance, and fatigue, all of which can significantly diminish an individual’s quality of life. The active compounds found in cannabis, known as cannabinoids, have been shown through clinical research to possess properties that may alleviate these symptoms. Studies have indicated that cannabinoids can not only lessen the neurological disability often seen in multiple sclerosis patients, but they can also mitigate the progressively deteriorating symptoms associated with the disease. That being said, the therapeutic application of cannabis does not come without its share of caveats. While the benefits of medicinal cannabis in managing multiple sclerosis symptoms are promising, it’s imperative to approach its usage with a prudent sense of caution. There are potential risks associated with the use of medicinal cannabis, including the possibility of dependency and the emergence of mental health issues. These risks are not to be taken lightly and necessitate careful consideration and thorough discussion between patients and their healthcare providers. The use of medicinal cannabis should always be under the strict guidance of a healthcare professional who is well-versed in its therapeutic application. This way, patients can be monitored for potential side effects, and dosage can be adjusted as required to ensure the most effective and safe treatment plan. The field of medicinal cannabis research is an ever-evolving one. As scientists continue to delve into the therapeutic properties and potential applications of cannabis, our understanding of how to use this plant for medicinal purposes will likely expand. The continued dedication to cannabis research promises to uncover new treatment pathways for a wide range of health conditions beyond multiple sclerosis. It is hoped that this ongoing research will lead to a more nuanced understanding of the risks and benefits of medicinal cannabis, allowing healthcare providers to make informed decisions and tailor treatment plans to best suit individual patient needs. This holds significant promise for countless patients worldwide who suffer from not only multiple sclerosis but also a host of other chronic conditions that may potentially be alleviated with the use of medicinal cannabis. For these individuals, the potential benefits of cannabis may offer a beacon of hope in their journey towards improved health and an enhanced quality of life.

You might be interested in exploring more about medicinal cannabis and its benefits. Speaking of cannabis, you might be interested in Cannabis as a plant commonly used for medical purposes. It has been legalized for medicinal use in many jurisdictions worldwide due to its therapeutic potential. Another related topic is chronic pain, which affects a significant portion of the global population. To learn more about chronic pain, you might want to check out Chronic pain on Wikipedia. Additionally, if you are curious about multiple sclerosis and ongoing research related to medicinal cannabis

Epilepsy is a neurological disorder that affects millions of people worldwide. It is characterized by recurrent seizures that can be debilitating and life-threatening. While there are many treatments available for epilepsy, some people have found relief in medicinal cannabis.

According to the UK-based charity Epilepsy Action, medical cannabis is legal in the UK and can be prescribed by specialist doctors to treat epilepsy ¹. The two most important chemicals in cannabis are cannabidiol (CBD) and tetrahydrocannabinol (THC). CBD does not have the mood-altering effects often associated with cannabis, and there has been a lot of research into its potential as an epilepsy treatment ¹. THC, on the other hand, is the part of the cannabis plant that makes people feel “high,” and more research is needed to find out if products containing THC are safe or effective for treating epilepsy ¹.

At the moment, there is one cannabis-based medicine that has been approved for treating epilepsy in the UK, called Epidyolex. It contains pure CBD and does not contain any THC. Epidyolex is available on the NHS as a treatment option for some people with epilepsy ¹. However, only some people with epilepsy are likely to be offered treatment with Epidyolex on the NHS. The National Institute for Health and Care Excellence (NICE) makes recommendations about what medicines doctors can prescribe on the NHS. NICE says that Epidyolex can be used as an add-on treatment option for people with Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous sclerosis complex (TSC) ¹.

While research is still ongoing, some studies have shown that medicinal cannabis can reduce the severity and frequency of seizures in some people, especially in children who have severe epilepsy syndromes such as Dravet and Lennox Gastaut Syndrome ². However, the American Academy of Neurology conducted a systematic review of the efficacy and safety of medical marijuana in selected neurological disorders and found that the use of oral cannabinoids are of unknown efficacy in epilepsy, that the risks and benefits of medical marijuana should be weighed carefully, and that the comparative effectiveness of medical marijuana versus already established therapies is unknown for epilepsy ³.

In conclusion, medicinal cannabis is a promising treatment option for epilepsy, but more research is needed to determine its efficacy and safety. If you or someone you know is considering medicinal cannabis as a treatment option, it is important to consult with a healthcare professional first.

¹: https://www.epilepsy.org.uk/info/treatment/medical-cannabis-based-treatments ²: https://www.epilepsy.org.au/about-epilepsy/medicinal-cannabis/ ³: https://epilepsycentre.org.au/medicinal-cannabis-in-the-treatment-of-epilepsy/

Learn more:

1. epilepsy.org.uk2. epilepsy.org.au3. epilepsycentre.org.au4. epilepsy.com5. epilepsy.org.uk

A recent scientific investigation has unearthed a potential link between past consumption of cannabis and a reduced likelihood of developing urological conditions, including bladder and prostate cancer. Although the influence of cannabis use on urological malignancies has remained ambiguous and largely undetermined until now, this study offers a fresh perspective that suggests cannabis use could be associated with a diminished risk of such medical conditions. This research was orchestrated by a multifaceted and globally diverse team of researchers hailing from China, the United Kingdom, and France. They meticulously analyzed the cannabis consumption habits of a substantial pool of 151,945 individuals over a four-year period from 2006 to 2010. The data for this extensive population sample was collected from the UK Biobank, a substantial resource of genetic and health information that offers a rich dataset for in-depth analyses. The researchers employed multivariable analysis in their study, an advanced statistical method that allows for controlling multiple factors at once. This approach provides a more accurate and insightful understanding of the relationships between different variables. To their surprise, their findings revealed that prior use of cannabis emerged as a “significant protective factor” against the development of renal cell carcinoma and prostate cancer. Renal cell carcinoma is recognized as one of the ten most prevalent cancers in the United States and is responsible for a staggering 90 percent of all kidney cancer diagnoses. This makes the study’s findings particularly noteworthy because they suggest a potential protective role of cannabis use against this commonly diagnosed and often deadly type of cancer. In addition, prostate cancer, the other condition that the study found to be less likely among previous users of cannabis, is the most frequently diagnosed cancer among men in the United Kingdom. Every year, approximately 52,300 new cases are reported, accounting for a significant proportion of the total cancer burden in the country. This reality underscores the potential importance and relevance of this study’s findings, as the discovery of any factor that could potentially lower prostate cancer risk could have a significant impact on public health. To summarize, the groundbreaking study conducted by researchers from China, the UK, and France offers compelling evidence of a possible link between prior cannabis use and a decreased risk of developing renal cell carcinoma and prostate cancer. The scientific community may, therefore, need to reconsider its understanding of the health implications of cannabis use. However, it is important to mention that while these findings are promising, they should not be considered as a definitive endorsement of cannabis use for cancer prevention. Further research is needed to confirm these findings and to more fully understand the potential risks and benefits of cannabis use.

A recent scientific investigation has found a potential link between past consumption of cannabis and a reduced likelihood of developing urological conditions, including bladder and prostate cancer ¹. The study was conducted by a team of researchers from China, the United Kingdom, and France who analyzed the cannabis consumption habits of 151,945 individuals over a four-year period from 2006 to 2010. The researchers employed multivariable analysis in their study, an advanced statistical method that allows for controlling multiple factors at once. Their findings revealed that prior use of cannabis emerged as a “significant protective factor” against the development of renal cell carcinoma and prostate cancer ¹. Renal cell carcinoma is recognized as one of the ten most prevalent cancers in the United States and is responsible for a staggering 90 percent of all kidney cancer diagnoses ¹. This makes the study’s findings particularly noteworthy because they suggest a potential protective role of cannabis use against this commonly diagnosed and often deadly type of cancer. In addition, prostate cancer, the other condition that the study found to be less likely among previous users of cannabis, is the most frequently diagnosed cancer among men in the United Kingdom. Every year, approximately 52,300 new cases are reported ¹.

I hope this helps!

Learn more:

1. cannabishealthnews.co.uk2. cannigma.com3. saiu.ca

The German government has recently announced that it will permit pharmacies to sell low-dose cannabis products without a prescription. The new law, which is expected to take effect in early 2024, will allow pharmacies to sell cannabis products with up to 2% THC¹. This move is a significant step forward in Germany’s cannabis policy and is expected to benefit patients who require cannabis for medical purposes.

It is worth noting that the use of cannabis for recreational purposes remains illegal in Germany. However, the country has been gradually relaxing its cannabis laws in recent years. In 2017, Germany legalized cannabis for medical purposes, and since then, the number of patients using cannabis for medical reasons has increased significantly².

This new law is expected to make it easier for patients to access cannabis products with low levels of THC, which are often used to treat conditions such as chronic pain, anxiety, and insomnia³. The law is also expected to benefit the German economy by creating new jobs and generating tax revenue³.

It is important to note that the sale of cannabis products with more than 2% THC will still require a prescription from a doctor¹. Additionally, the use of cannabis products for recreational purposes remains illegal in Germany¹.

¹: The Guardian ²: Deutsche Welle ³: CNN

Learn more:

1. theguardian.com2. bbc.com3. cms.law

Intelicanna, a pioneering Israeli firm, has made significant strides in the medicinal cannabis industry with its development of an innovative inhalable cannabis solution known as the Cannabinoid Medical Device (CMD). The primary aim of this groundbreaking product is to provide an effective treatment for individuals suffering from pain and inflammation. The CMD is ingeniously designed as a compact, handheld inhaler that seamlessly delivers an accurate dose of cannabis directly to the lungs. The groundbreaking technology behind it ensures that each puff delivers cannabis in a pure, unadulterated form, making it a potentially transformative tool in pain and inflammation management. The CMD is currently under rigorous clinical trials, with Intelicanna optimistically planning to introduce it to the market by 2024. What sets CMD apart from traditional methods of cannabis intake, such as smoking or vaping, is its convenience and efficacy. Unlike these conventional methods, CMD ensures that each dose of cannabis is delivered in a clean, precise manner, thus increasing the overall effectiveness of the treatment. Moreover, in an era where discreetness is highly valued, CMD is designed to be inconspicuous. It does not produce any smoke or odor, making it a discreet option for patients who want to use it in public or in the presence of others. This feature not only enhances user comfort but also contributes to reducing the stigma associated with cannabis use. While CMD is still in the early stages of development, it stands out as a potentially significant breakthrough in the treatment of pain and inflammation. If clinical trials prove its safety and effectiveness, the CMD could revolutionize the way patients manage their pain, offering a fresh, innovative, and most importantly, effective method of treatment. It could change the landscape of pain management, improving the quality of life for countless patients. In conclusion, the excitement around the clinical trials for CMD is palpable. There is a strong belief that it has the potential to be an invaluable resource for patients who are grappling with pain and inflammation. With its precision, discreetness, and overall effectiveness in delivering medicinal cannabis, CMD could soon be at the forefront of pain management solutions. This makes it an eagerly awaited product, and the medical world is watching keenly to see the results of the ongoing clinical trials.

Researchers at the University of California, San Francisco have developed a new interactive mapping tool that shows the distribution and use of highly concentrated cannabis products in the US. The tool is based on data from a variety of sources, including state cannabis regulators, public health surveys, and research studies.

The tool shows that the use of highly concentrated cannabis products is increasing rapidly in many parts of the US. For example, the percentage of people who reported using cannabis concentrates in the past year increased from 1.7% in 2011 to 10.3% in 2020. The tool also shows that the use of highly concentrated cannabis products is more common among certain groups, such as young people, men, and people who use cannabis regularly.

The tool is designed to help policymakers better understand the distribution and use of highly concentrated cannabis products so that they can develop effective policies to regulate these products. The tool can also be used by researchers to study the health effects of highly concentrated cannabis products and to develop educational programs to help consumers use these products safely.

The development of this new interactive mapping tool is an important step forward in our understanding of highly concentrated cannabis products. The tool will help policymakers, researchers, and consumers to better understand these products and to develop effective policies and educational programs to reduce the potential risks associated with their use.

The latest research published in the renowned journal JAMA Internal Medicine has discovered a significant correlation between the use of marijuana and an elevated risk for heart-related ailments, specifically heart attack and heart failure. The study examined a large sample size of data gathered from over 100,000 individuals, providing a robust perspective on this critical health issue. What was particularly noteworthy was that individuals who regularly consumed marijuana were found to have a higher likelihood of suffering from a heart attack or heart failure as compared to their counterparts who refrained from marijuana use. This key finding underscores the potential health risks associated with the frequent usage of marijuana, debunking the prevalent myth of its harmlessness. The authors of the study suggested that the increased risk of heart attack and heart failure associated with marijuana use is likely attributable to the effects of Tetrahydrocannabinol (THC), the principal psychoactive compound present in marijuana. THC has been known to stimulate the heart rate and escalate blood pressure, both of which can exert considerable stress on the heart, thus potentially leading to serious cardiac complications. Furthermore, THC may also disrupt the process of blood clotting, thereby potentially increasing the risk of the formation of dangerous blood clots in the heart. Such clots can obstruct blood flow, potentially leading to life-threatening conditions like a heart attack or stroke. The implications of this study are significant as they challenge the common perception that marijuana use is predominantly safe. It behooves individuals who regularly consume marijuana to be cognizant of the potential health risks associated with its use. This cautionary advice holds particularly true for those who already have other risk factors for heart disease, such as high blood pressure, elevated cholesterol levels, or diabetes. However, it is crucial to clarify that this study is observational in nature, implying that it can’t conclusively establish that marijuana use directly causes heart attack or heart failure. Despite this, the study’s findings do insinuate a potential correlation between the two. More comprehensive research is warranted to not only validate this link but also to elucidate the exact mechanisms through which marijuana use may heighten the risk of heart attack and heart failure. It is only through such rigorous, empirical research that a more definitive understanding of the relationship between marijuana use and heart health can be attained. This would, in turn, enable healthcare professionals to provide more nuanced advice to patients regarding the potential implications of marijuana use on their cardiac health.

A new study published in the journal JAMA Internal Medicine found that marijuana use is linked with an increased risk of heart attack and heart failure ¹²³. The study analyzed data from over 100,000 people and found that those who used marijuana regularly were more likely to experience a heart attack or heart failure than those who did not use marijuana.

The study’s authors say that the increased risk of heart attack and heart failure associated with marijuana use is likely due to the effects of THC, the main psychoactive compound in marijuana. THC can cause the heart rate to increase and blood pressure to rise, both of which can put stress on the heart. Additionally, THC can interfere with blood clotting, which can increase the risk of blood clots forming in the heart.

The study’s findings are important because they suggest that marijuana use may not be as safe as some people believe. People who use marijuana should be aware of the potential risks associated with use, especially if they have other risk factors for heart disease, such as high blood pressure, high cholesterol, or diabetes.

It is important to note that the study is observational, meaning that it cannot prove that marijuana use causes heart attack or heart failure. However, the study’s findings do suggest that there is a link between the two. More research is needed to confirm the link and to understand the mechanisms by which marijuana use may increase the risk of heart attack and heart failure.

• Marijuana use linked with increased risk of heart failure and heart attack: New studies
• Marijuana use raises risk of heart attack, heart failure and stroke, studies say

Learn more:

1. msn.com2. msn.com3. newsroom.heart.org4. dailymail.co.uk5. webmd.com6. webmd.com— see less

Marijuana use linked with increased risk of heart attack, heart failure

American Heart Association Scientific Sessions 2023, Abstract Poster MDP250 and Abstract Poster MDP249

DALLAS, Nov. 6, 2023 — Using marijuana regularly may raise the risk for heart failure, stroke or heart attack even after accounting for other cardiovascular risk factors such as Type 2 diabetes, high blood pressure and obesity, according to two preliminary studies to be presented at the American Heart Association’s Scientific Sessions 2023. The meeting, to be held Nov. 11-13, in Philadelphia, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.

The use of marijuana, medically known as cannabis, is gaining popularity across the U.S. as more states legalize it for recreational and medical use. However, how marijuana affects the heart and brain health is still not completely known. Two new studies, by separate research groups, shed light on the association for regular marijuana use with risk for heart failure, heart attack and stroke.

Daily marijuana use is associated with incident heart failure: “All of Us” Research Program (Poster Abstract MDP250)

More than 150,000 adults in the U.S. participated in the All of Us Research Program, a National Institutes of Health-sponsored program. Researchers focused on the relationship between lifestyle, biology and environment in diverse populations and analyzed the association between daily marijuana use and heart failure.

“Prior research shows links between marijuana use and cardiovascular disease like coronary artery disease, heart failure and atrial fibrillation, which is known to cause heart failure,” said lead study author Yakubu Bene-Alhasan, M.D., M.P.H., a resident physician at Medstar Health in Baltimore. “Marijuana use isn’t without its health concerns, and our study provides more data linking its use to cardiovascular conditions.”

Bene-Alhasan and colleagues followed 156,999 individuals who were free from heart failure at the time they enrolled in the research program. Study participants completed a survey about the frequency of their marijuana use and were followed for nearly 4 years (45 months). The analysis was adjusted to account for individual demographic and economic factors, alcohol use, smoking and other cardiovascular risk factors linked with heart failure, such as Type 2 diabetes, high blood pressure, high cholesterol and obesity.

The analysis found:

• During the study period, 2,958 people (almost 2%) developed heart failure.
• People who reported daily marijuana use had a 34% increased risk of developing heart failure, compared to those who reported never using marijuana. This risk was the same regardless of age, sex at birth or smoking history.
• In a secondary analysis, when coronary artery disease was added to the investigation, the risk of heart failure dropped from 34% to 27%, suggesting that coronary artery disease is a pathway through which daily marijuana use may lead to heart failure.

“Our results should encourage more researchers to study the use of marijuana to better understand its health implications, especially on cardiovascular risk,” Bene-Alhasan said. “We want to provide the population with high-quality information on marijuana use and to help inform policy decisions at the state level, to educate patients and to guide health care professionals.”

Study details:

• The definition of marijuana use was using marijuana when not prescribed for a health condition, or, if prescribed for medical purposes, using it beyond that purpose.
• The median participant age was 54 years; 60.9% of participants were female at birth; 70.7% self-identified as white adults; 21.8% were Black or African American adults; 4.2% were Asian adults; 2.2% were identified as more than one race/ethnicity; and 1.1% were from other races/ethnicities.
• The study enrollment began in June 2016. Participants were followed from when they enrolled until June 2022, a maximum of approximately 4 years (45 months).

A limitation of the study is that it relied on data that did not specify whether the marijuana was inhaled or eaten. According to researchers, how marijuana is ingested may influence cardiovascular outcomes.

Co-authors, their disclosures and funding sources are listed in the abstract.

Increased risk of major adverse cardiac and cerebrovascular events in elderly non-smokers who use cannabis (Poster Abstract MDP249)

In a second study, different researchers evaluated data from the 2019 National Inpatient Sample, the largest nationwide database of hospitalizations, to investigate whether hospital stays were complicated by a cardiovascular event, including heart attack, stroke, cardiac arrest or arrhythmia in patients who used marijuana. Researchers extracted records on adults older than age 65 years with cardiovascular risk factors who reported no tobacco use (cigarettes or other tobacco products). This group of patient records were then divided into two groups: marijuana users and non-marijuana users. The marijuana user’s hospital records were coded for cannabis use disorder which can vary from hospital to hospital.

“Since 2015, cannabis use in the U.S. has almost doubled, and it is increasing in older adults, therefore, understanding the potential increased cardiovascular risk from cannabis use is important,” said lead study author Avilash Mondal, M.D., a resident physician at Nazareth Hospital in Philadelphia. “What is unique about our study is that patients who were using tobacco were excluded because cannabis and tobacco are sometimes used together, therefore, we were able to specifically examine cannabis use and cardiovascular outcomes.”

The study found of the 28,535 cannabis users with existing cardiovascular risk factors (high blood pressure, Type 2 diabetes or high cholesterol):

• 20% had an increased chance of having a major heart or brain event while hospitalized, compared to the group who did not use cannabis.
• 13.9% of cannabis users with cardiovascular risk factors had a major adverse heart and brain event while hospitalized compared to non-cannabis users.
• Additionally, the cannabis users in comparison to non-cannabis users had a higher rate of heart attacks (7.6% versus 6%, respectively) and were more likely to be transferred to other facilities (28.9% vs. 19%).
• High blood pressure (defined as greater than 130/80 mm Hg) and high cholesterol were predictors of major adverse heart and brain events in marijuana users.

“We must be mindful about major heart and stroke events in older adults with cannabis use disorder. At this point, we need more studies to understand the long-term effects of cannabis use,” Mondal said. “Health care professionals should include the question, ‘Are you using cannabis?’ when taking a patient’s history. If you ask patients if they are smoking, people think cigarette smoking. The main public message is to be more aware of the increased risks and open the lines of communication so that cannabis use is acknowledged and considered.”

A limitation of the analysis is that the data is from a large database, which may have coding errors in the patients’ health records. In addition, the electronic health record code for cannabis use disorder may vary from hospital to hospital, thereby skewing the results of the analysis.

Study details:

• 2019 National Inpatient Sample health records were reviewed for 28,835 adults with cannabis use disorder and high blood pressure, Type 2 diabetes or high cholesterol. The comparison group included 10,680,000 adults with the same risk factors who did not use marijuana.
• Researchers examined hospitalization records to analyze the incidence of in-hospital cardiovascular disease events for adults in both groups.
• 69.5% of participants in the cannabis use disorder group were male and 30.5% were female. In contrast, 45.8% were males in the non-cannabis use group versus 54.2 in the female non-use group.
• Health records of race according to cannabis use versus non-use , respectively was: 70.2% versus 76.4 among white adults; 20.1% versus 10.8% among Black adults; 5.6% versus 7.4% among Hispanic adults; 0.70% versus 2.7% among Asian or Pacific Islander adults; and 1% versus 0.40% among Native American adults.

“The latest research about cannabis use indicates that smoking and inhaling cannabis increases concentrations of blood carboxyhemoglobin (carbon monoxide, a poisonous gas), tar (partly burned combustible matter) similar to the effects of inhaling a tobacco cigarette, both of which have been linked to heart muscle disease, chest pain, heart rhythm disturbances, heart attacks and other serious conditions,” said Robert L. Page II, Pharm.D., M.S.P.H., FAHA, chair of the volunteer writing group for the 2020 American Heart Association Scientific Statement: Medical Marijuana, Recreational Cannabis, and Cardiovascular Health. “Together with the results of these two research studies, the cardiovascular risks of cannabis use are becoming clearer and should be carefully considered and monitored by health care professionals and the public.”

Page is professor, Departments of Clinical Pharmacy and Physical Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Anschutz Campus, in Aurora, Colorado.

Co-authors, their disclosures and funding sources are listed in the abstract.

Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.

The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.

Additional Resources:

• Video interview with AHA volunteer expert: Robert L. Page II, Pharm.D., M.S.P.H., FAHA,  and other multimedia is available on the right column of the release link https://newsroom.heart.org/news/marijuana-use-linked-with-increased-risk-of-heart-attack-heart-failure?preview=796f90faf6bf570f13745845188dcf12
• After Nov. 6, view Abstract Poster MDP250 and Abstract Poster MDP249 in the AHA Scientific Sessions 2023 Online Program Planner
• Spanish News Release
• AHA news release: Depression & anxiety symptoms linked to vaping nicotine and THC in teens and young adults (Feb. 2023)
• AHA news release: How does cannabis use affect brain health? Caution advised, more research needed (Feb. 2022)
• About Scientific Sessions 2023  
• For more news at AHA Scientific Sessions 2023, follow us on X (formerly known as Twitter) @HeartNews,#AHA23

Medicinal cannabis, also known as medical marijuana, is increasingly recognized for its potential benefits in various medical conditions, including muscle recovery. The two primary active compounds in cannabis, THC (tetrahydrocannabinol) and CBD (cannabidiol), have shown promising results in assisting the body’s healing processes, reducing inflammation, and alleviating pain. Muscle recovery is a critical aspect of any physical training regimen. After a strenuous workout, muscles become inflamed and damaged, initiating a healing process that can lead to muscle growth and increased strength. However, this process often involves discomfort and a significant amount of time for recovery. Inflammation is a natural part of the body’s healing process. However, excessive inflammation can delay recovery and cause pain. One of the primary benefits of medicinal cannabis, especially CBD, is its anti-inflammatory properties. A study published in the European Journal of Pain revealed that CBD could help decrease pain and inflammation in rats. While more research is needed to fully understand this process in humans, these findings suggest that cannabis could potentially reduce inflammation and help speed up the muscle recovery process. Pain is another significant factor in muscle recovery. Pain can limit mobility and hinder the recovery process. Both THC and CBD have shown analgesic, or pain-relieving, properties. Many athletes who use medicinal cannabis report less pain during the recovery process, which can contribute to more effective healing and a quicker return to physical activity. Medicinal cannabis may also help with muscle spasms, a common issue faced during the muscle recovery phase. Muscle spasms or cramps are sudden, involuntary contractions that can be extremely painful. According to the American Academy of Neurology, certain forms of medical cannabis can help alleviate symptoms of spasticity, including muscle spasms. Sleep is an often-overlooked factor in muscle recovery. During sleep, the body produces growth hormone, which plays a pivotal role in muscle growth and recovery. THC, the psychoactive compound in cannabis, has been shown to help users fall asleep faster and increase the deep sleep stages necessary for muscle recovery. While research into the benefits of medicinal cannabis for muscle recovery is ongoing, initial studies and anecdotal evidence suggest that cannabis could play a beneficial role in reducing inflammation, relieving pain, controlling muscle spasms, and promoting better sleep. As always, individuals should consult with a healthcare provider before starting any new treatment regimen.

Research has shown that medicinal cannabis may have potential benefits for muscle recovery. According to a study by LISS Cardio, cannabis can help with muscle recovery in three ways ¹:

1. Managing inflammation: Cannabis compounds have natural anti-inflammatory properties that can help soothe sore muscles and reduce inflammation in the target muscles, joints, and surrounding areas.
2. Boosting recovery by regulating sleep: Muscle-building is a process that swings like a pendulum between exercise and recovery. Cannabis compounds can help regulate sleep, which is essential for muscle recovery.
3. Filling in nutritional gaps: Cannabis compounds can help fill in nutritional gaps that may be preventing optimal muscle recovery.

However, it’s important to note that research on the effects of medicinal cannabis on muscle recovery is still in its early stages, and more research is needed to fully understand its potential benefits and risks. It’s also important to consult with a healthcare professional before using medicinal cannabis for any purpose ²¹.

Learn more:

1. lisscardio.com2. newscientist.com3. leafwell.com4. capitalfm.co.ke5. bbc.com

Medicinal cannabis, also known as medical marijuana, has shown promising results in assisting the body’s healing processes, reducing inflammation, and alleviating pain, which are critical aspects of muscle recovery ¹. The two primary active compounds in cannabis, THC (tetrahydrocannabinol) and CBD (cannabidiol), have demonstrated anti-inflammatory and analgesic properties, respectively ¹. Inflammation is a natural part of the body’s healing process. However, excessive inflammation can delay recovery and cause pain. One of the primary benefits of medicinal cannabis, especially CBD, is its anti-inflammatory properties. A study published in the European Journal of Pain revealed that CBD could help decrease pain and inflammation in rats. While more research is needed to fully understand this process in humans, these findings suggest that cannabis could potentially reduce inflammation and help speed up the muscle recovery process ¹. Pain is another significant factor in muscle recovery. Pain can limit mobility and hinder the recovery process. Both THC and CBD have shown analgesic, or pain-relieving, properties. Many athletes who use medicinal cannabis report less pain during the recovery process, which can contribute to more effective healing and a quicker return to physical activity ¹. Medicinal cannabis may also help with muscle spasms, a common issue faced during the muscle recovery phase. Muscle spasms or cramps are sudden, involuntary contractions that can be extremely painful. According to the American Academy of Neurology, certain forms of medical cannabis can help alleviate symptoms of spasticity, including muscle spasms ¹. Sleep is an often-overlooked factor in muscle recovery. Sleep is essential for muscle recovery, and cannabis compounds can help regulate sleep, which is essential for muscle recovery ¹. However, it’s important to note that research on the effects of medicinal cannabis on muscle recovery is still in its early stages, and more research is needed to fully understand its potential benefits and risks. It’s also important to consult with a healthcare professional before using medicinal cannabis for any purpose ¹.

Learn more:

1. newscientist.com2. lisscardio.com3. leafwell.com4. capitalfm.co.ke5. bbc.com

Imperial College London is one of the leading universities in the world, known for its high-quality research and teaching. In recent years, it has been at the forefront of medicinal cannabis research, exploring its potential therapeutic benefits and working towards understanding its mechanisms of action. The research at Imperial College London investigates various aspects of medicinal cannabis, including its effects on various medical conditions such as epilepsy, multiple sclerosis, chronic pain, and mental health disorders. The aim is to determine the efficacy of cannabis-derived compounds in treating these conditions and their potential side effects. One of the key research projects at Imperial College London is the investigation of the use of cannabinoids in the treatment of epilepsy. Epilepsy is a neurological disorder marked by sudden recurrent episodes of sensory disturbance, loss of consciousness, or convulsions, associated with abnormal electrical activity in the brain. This study aims to determine whether cannabinoids can help reduce the frequency and severity of seizures in epilepsy patients. Other research at the Imperial College London focuses on the effects of medicinal cannabis on mental health disorders, particularly anxiety and depression. The researchers are investigating whether cannabis compounds can help improve mood and reduce anxiety levels in patients with these disorders. Alongside these specific research projects, Imperial College London is also engaged in broad-ranging research into the pharmacology of cannabis. This involves studying how the body responds to various cannabis compounds and how these compounds interact with each other. The research on medicinal cannabis at Imperial College London is carried out in strict accordance with UK law and regulation, ensuring the highest standards of ethics and safety. It contributes to our understanding of how cannabis and its compounds work in the human body, and may pave the way for new treatments for a variety of medical conditions. In conclusion, Imperial College London is making significant contributions to the field of medicinal cannabis research. Through a comprehensive and scientific approach, it is providing valuable insights into the therapeutic potential of cannabis and its various compounds.

The university has a number of research groups working on different aspects of medicinal cannabis, including the following:

• The Medical Cannabis Research Group is led by Dr. Istvan Nagy and is dedicated to understanding the therapeutic potential of cannabinoids and developing new cannabinoid-based therapies. The group has conducted research on the use of cannabinoids to treat a variety of conditions, including cancer, acute pain, and nausea and vomiting.
• The Centre for Psychedelic Research is led by Professor Robin Carhart-Harris and is dedicated to the study of psychedelic drugs, including cannabis. The center has conducted research on the use of cannabis to treat a variety of conditions, including anorexia, chronic pain, and OCD.
• The Institute of Cancer Research (ICR) is a research institute that is closely affiliated with Imperial College London. The ICR has a number of research groups working on different aspects of cancer research, including the use of cannabinoids to treat cancer.

In addition to these specific research groups, there are a number of other researchers at Imperial College London who are conducting research on medicinal cannabis. This research is funded by a variety of sources, including the UK government, the National Institute for Health Research, and charitable foundations.

The research on medicinal cannabis at Imperial College London is helping to advance our understanding of the potential benefits and risks of cannabis use, and it is leading to the development of new cannabinoid-based therapies for a variety of conditions.

Here are some specific examples of medicinal cannabis research projects that are currently underway at Imperial College London:

• A clinical trial of a cannabinoid-based drug for the treatment of acute post-operative pain, nausea, and vomiting. This trial is being led by Dr. Istvan Nagy and is funded by the National Institute for Health Research. The trial is expected to be completed in 2024.
• A study of the effects of cannabinoids on cancer cells and the tumor microenvironment. This study is being led by Dr. Anguraj Sadanandam and is funded by the Cancer Research UK. The study is expected to be completed in 2025.
• A study of the use of cannabinoids to treat anorexia in patients with cancer. This study is being led by Professor Robin Carhart-Harris and is funded by the Medical Research Council. The study is expected to be completed in 2026.

These are just a few examples of the many medicinal cannabis research projects that are currently underway at Imperial College London. The university’s research on medicinal cannabis is helping to advance our understanding of the potential benefits and risks of cannabis use, and it is leading to the development of new cannabinoid-based therapies for a variety of conditions.

Imperial College London is a renowned institution that has been at the forefront of medicinal cannabis research in recent years. The research at Imperial College London investigates various aspects of medicinal cannabis, including its effects on various medical conditions such as epilepsy, multiple sclerosis, chronic pain, and mental health disorders ¹. One of the key research projects at Imperial College London is the investigation of the use of cannabinoids in the treatment of epilepsy. This study aims to determine whether cannabinoids can help reduce the frequency and severity of seizures in epilepsy patients ¹. Other research at the Imperial College London focuses on the effects of medicinal cannabis on mental health disorders, particularly anxiety and depression. The researchers are investigating whether cannabis compounds can help improve mood and reduce anxiety levels in patients with these disorders ¹. Alongside these specific research projects, Imperial College London is also engaged in broad-ranging research into the pharmacology of cannabis. This involves studying how the body responds to various cannabis compounds and how these compounds interact with each other ¹. The research on medicinal cannabis at Imperial College London is carried out in strict accordance with UK law and regulation, ensuring the highest standards of ethics and safety ¹. It contributes to our understanding of how cannabis and its compounds work in the human body, and may pave the way for new treatments.

Learn more:

1. imperial.ac.uk2. icr.ac.uk3. imperial.ac.uk

Oxford University, one of the world’s leading academic institutions, has launched an extensive research program into the potential benefits of medicinal cannabis. The program aims to explore the role that cannabis can play in treating pain, cancer, and inflammatory diseases. This research has been made possible by a multimillion-pound donation from Kingsley Capital Partners, a private equity firm focused on healthcare and life sciences. The research program has two main objectives. Firstly, it aims to understand the biology of medicinal cannabis, including its physiological and therapeutic effects on the human body. To do this, researchers are conducting a series of rigorous clinical trials and are also studying the molecular structure of different cannabis strains to identify the unique compounds that make them effective in treating certain conditions. Secondly, the program aims to develop new therapies based on the medicinal properties of cannabis. These therapies could offer new treatment options for people suffering from chronic pain, cancer, and other serious conditions. The researchers are particularly interested in the potential of cannabinoids – the active compounds in cannabis – to relieve pain and inflammation, reduce nausea and vomiting in cancer patients undergoing chemotherapy, and improve sleep and appetite in people with certain neurological disorders. Oxford University’s medicinal cannabis research is considered groundbreaking, as it has the potential to transform our understanding of cannabis and health. It’s also likely to have a significant impact on the pharmaceutical industry and on legislation around the world. The research could lead to the development of new drugs that harness the medicinal properties of cannabis, while also providing hard scientific evidence to inform policy debates on the legalization of medicinal cannabis. The researchers at Oxford are collaborating with other leading scientists around the world, sharing their findings and insights to advance the global understanding of cannabis and its potential medical uses. They’re also working to debunk common myths about cannabis, based on the best scientific evidence available. In conclusion, Oxford University’s medicinal cannabis research program is pioneering the way in understanding the medicinal properties of cannabis and its potential therapeutic applications. As the research progresses, it holds the promise of unlocking new treatment options for many people suffering from chronic and debilitating conditions.

The university has a number of research groups working on different aspects of medicinal cannabis, including the following:

• The Cannabinoid Research Group is led by Professor David Baker and is dedicated to understanding the mechanisms of action of cannabinoids and developing new cannabinoid-based therapies. The group has conducted research on the use of cannabinoids to treat a variety of conditions, including chronic pain, cancer, and epilepsy.
• The Centre for Evidence-Based Medicine is led by Professor Carl Heneghan and is known for its rigorous and independent approach to research. The center has conducted research on the effectiveness and safety of medicinal cannabis for a variety of conditions.
• The Oxford Cannabinoid Technologies (OCT) is a spin-out company from Oxford University that is developing new cannabinoid-based therapies for a variety of conditions. OCT has a number of clinical trials underway, including a trial of a cannabinoid-based drug for the treatment of chronic pain.

In addition to these specific research groups, there are a number of other researchers at Oxford University who are conducting research on medicinal cannabis. This research is funded by a variety of sources, including the UK government, the National Institute for Health Research, and charitable foundations.

The research on medicinal cannabis at Oxford University is helping to advance our understanding of the potential benefits and risks of cannabis use, and it is leading to the development of new cannabinoid-based therapies for a variety of conditions.

Here are some specific examples of medicinal cannabis research projects that are currently underway at Oxford University:

• A clinical trial of a cannabinoid-based drug for the treatment of chronic pain. This trial is being led by Professor David Baker and is funded by the UK government. The trial is expected to be completed in 2024.
• A study of the effectiveness of cannabinoids for the treatment of epilepsy. This study is being led by Dr. Sanjay Aggarwal and is funded by the National Institute for Health Research. The study is expected to be completed in 2025.
• A study of the safety and efficacy of cannabinoids for the treatment of cancer. This study is being led by Professor David Fennell and is funded by Cancer Research UK. The study is expected to be completed in 2026.

These are just a few examples of the many medicinal cannabis research projects that are currently underway at Oxford University. The university’s research on medicinal cannabis is helping to advance our understanding of the potential benefits and risks of cannabis use, and it is leading to the development of new cannabinoid-based therapies for a variety of conditions.

Oxford University has several research groups dedicated to studying medicinal cannabis, including the Cannabinoid Research Group, the Centre for Evidence-Based Medicine, and the Oxford Cannabinoid Technologies (OCT) ¹. The Cannabinoid Research Group, led by Professor David Baker, is focused on understanding the mechanisms of action of cannabinoids and developing new cannabinoid-based therapies. The group has conducted research on the use of cannabinoids to treat a variety of conditions, including chronic pain, cancer, and epilepsy ¹. The Centre for Evidence-Based Medicine, led by Professor Carl Heneghan, is known for its rigorous and independent approach to research. The center has conducted research on the effectiveness and safety of medicinal cannabis for a variety of conditions ¹. The OCT is a spin-out company from Oxford University that is developing new cannabinoid-based therapies for a variety of conditions. OCT has a number of clinical trials underway, including a trial of a cannabinoid-based drug for the treatment of chronic pain ¹.

In addition to these specific research groups, there are a number of other researchers at Oxford University who are conducting research on medicinal cannabis. This research is funded by a variety of sources, including the UK government, the National Institute for Health Research, and charitable foundations ¹.

The research on medicinal cannabis at Oxford University is helping to advance our understanding of the potential benefits and risks of cannabis use, and it is leading to the development of new cannabinoid-based therapies for a variety of conditions ¹. Some specific examples of medicinal cannabis research projects that are currently underway at Oxford University include a clinical trial of a cannabinoid-based drug for the treatment of chronic pain, which is being led by Professor David Baker and is funded by the UK government. The trial is expected to be completed in 2024 ¹. Another study is investigating the effectiveness of cannabinoids for the treatment of epilepsy ¹.

Learn more:

1. academic.oup.com2. ox.ac.uk3. telegraph.co.uk4. theguardian.com